![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 51, 49127-49133, December 20, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Groupe de Recherche sur le Cancer du Poumon, INSERM-EMI
9924, Institut Albert Bonniot, La Tronche 38706 Cedex, France
Several abnormalities in the
insulin-like growth factor-1 (IGF1) and erbB receptors pathways
stimulate the growth and survival of lung cancer cells, but their
mechanisms of action and cooperation are poorly understood. In this
report, we have identified a new mechanism of apoptosis inhibition by
amphiregulin through an IGF1-dependent survival pathway in
non-small cell lung cancer (NSCLC) cells: amphiregulin activates the
IGF1 receptor that in turn induces the secretion of amphiregulin
and IGF1. In the absence of serum, the NSCLC cell line H358 resists
apoptosis and secretes factors protecting the NSCLC cell line H322 from
serum deprivation apoptosis. IGF1 receptor inhibitor AG1024 as well as
epidermal growth factor receptor inhibitors AG556 and ZD1839 restore
apoptosis in H322 cells cultured in H358-conditioned medium.
Accordingly, the anti-apoptotic activity of H358-conditioned medium is
completely abolished after incubation with anti-amphiregulin
neutralizing antibody and only partially with anti-IGF1 neutralizing
antibody. H358-conditioned medium and amphiregulin induce IGF1 receptor
phosphorylation in H322 cells, which is prevented by anti-amphiregulin
neutralizing antibody but not by AG556 or ZD1839. H358 cells secrete a
high level of amphiregulin that, in combination with IGF1, prevents serum deprivation apoptosis. Finally, IGF1 receptor inhibitor blocks
amphiregulin and IGF1 release by H358 cells.
Inhibition of Apoptosis by Amphiregulin via an Insulin-like
Growth Factor-1 Receptor-dependent Pathway in Non-small
Cell Lung Cancer Cell Lines*
,
§,
*
This work was supported by grants and research fellowships
from Association pour la Recherche contre le Cancer.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Both authors contributed equally to this work.
§
Present address: INSERM U517, Faculté de
Médecine/Pharmacie, 7 boulevard Jeanne d'Arc, Dijon 21033 cedex, France.
¶
To whom correspondence should be addressed: Tel.:
33-4-76-76-54-84; Fax: 33-4-76-76-56-64; E-mail:
MCFavrot@chu-grenoble.fr.
This article has been cited by other articles:
![]() |
N. Wakamatsu, J. B. Collins, J. S. Parker, M. Tessema, N. P. Clayton, T.-V. T. Ton, H.-H. L. Hong, S. Belinsky, T. R. Devereux, R. C. Sills, et al. Gene Expression Studies Demonstrate that the K-ras/Erk MAP Kinase Signal Transduction Pathway and Other Novel Pathways Contribute to the Pathogenesis of Cumene-induced Lung Tumors Toxicol Pathol, July 1, 2008; 36(5): 743 - 752. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Chakraborty, K. Liang, and M. P. DiGiovanna Co-Targeting Insulin-Like Growth Factor I Receptor and HER2: Dramatic Effects of HER2 Inhibitors on Nonoverexpressing Breast Cancer Cancer Res., March 1, 2008; 68(5): 1538 - 1545. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Nilsson, P. Eden, E. Olsson, R. Mansson, I. Astrand-Grundstrom, B. Strombeck, K. Theilgaard-Monch, K. Anderson, R. Hast, E. Hellstrom-Lindberg, et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes Blood, October 15, 2007; 110(8): 3005 - 3014. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Pinto-Plata, J. Toso, K. Lee, D. Park, J. Bilello, H. Mullerova, M. M De Souza, R. Vessey, and B. Celli Profiling serum biomarkers in patients with COPD: associations with clinical parameters Thorax, July 1, 2007; 62(7): 595 - 601. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Shinagawa, J. A. Martin, V. A. Ploplis, and F. J. Castellino Coagulation Factor Xa Modulates Airway Remodeling in a Murine Model of Asthma Am. J. Respir. Crit. Care Med., January 15, 2007; 175(2): 136 - 143. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Castillo, E. Erroba, M. J. Perugorria, M. Santamaria, D. C. Lee, J. Prieto, M. A. Avila, and C. Berasain Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res., June 15, 2006; 66(12): 6129 - 6138. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kalyankrishna and J. R. Grandis Epidermal Growth Factor Receptor Biology in Head and Neck Cancer J. Clin. Oncol., June 10, 2006; 24(17): 2666 - 2672. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Bayram, K. Ito, R. Issa, M. Ito, M. Sukkar, and K. F. Chung Regulation of human lung epithelial cell numbers by diesel exhaust particles Eur. Respir. J., April 1, 2006; 27(4): 705 - 713. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Knowlden, I. R. Hutcheson, D. Barrow, J. M. W. Gee, and R. I. Nicholson Insulin-Like Growth Factor-I Receptor Signaling in Tamoxifen-Resistant Breast Cancer: A Supporting Role to the Epidermal Growth Factor Receptor Endocrinology, November 1, 2005; 146(11): 4609 - 4618. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ishikawa, Y. Daigo, A. Takano, M. Taniwaki, T. Kato, S. Hayama, H. Murakami, Y. Takeshima, K. Inai, H. Nishimura, et al. Increases of Amphiregulin and Transforming Growth Factor-{alpha} in Serum as Predictors of Poor Response to Gefitinib among Patients with Advanced Non-Small Cell Lung Cancers Cancer Res., October 15, 2005; 65(20): 9176 - 9184. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hurbin, J.-L. Coll, L. Dubrez-Daloz, B. Mari, P. Auberger, C. Brambilla, and M.-C. Favrot Cooperation of Amphiregulin and Insulin-like Growth Factor-1 Inhibits Bax- and Bad-mediated Apoptosis via a Protein Kinase C-dependent Pathway in Non-small Cell Lung Cancer Cells J. Biol. Chem., May 20, 2005; 280(20): 19757 - 19767. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kakiuchi, Y. Daigo, N. Ishikawa, C. Furukawa, T. Tsunoda, S. Yano, K. Nakagawa, T. Tsuruo, N. Kohno, M. Fukuoka, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839) Hum. Mol. Genet., December 15, 2004; 13(24): 3029 - 3043. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Johansson, A. Yndestad, J. M. Enserink, A. H. Ree, P. Aukrust, and K. Tasken The Epidermal Growth Factor-Like Growth Factor Amphiregulin Is Strongly Induced by the Adenosine 3',5'-Monophosphate Pathway in Various Cell Types Endocrinology, November 1, 2004; 145(11): 5177 - 5184. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Mahtouk, M. Jourdan, J. De Vos, C. Hertogh, G. Fiol, E. Jourdan, J.-F. Rossi, and B. Klein An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis Blood, March 1, 2004; 103(5): 1829 - 1837. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Pedron, C. Thibault, and P. J. Sansonetti The Invasive Phenotype of Shigella flexneri Directs a Distinct Gene Expression Pattern in the Human Intestinal Epithelial Cell Line Caco-2 J. Biol. Chem., September 5, 2003; 278(36): 33878 - 33886. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |